Ajooni Biotech Ltd (AJOONI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1002898, "name": "Ajooni Biotech", "stock_name": "Ajooni Biotech", "full_name": "Ajooni Biotech Ltd", "name_url": "stocks-analysis/ajooni-biotech", "exchange": 1, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "4.93", "chg": -0.22, "chgp": "-4.27%", "dir": -1, "prev_price": "5.15", "mcapval": "93.00 Cr", "mcap": "Micro Cap", "scripcode": "", "symbol": "AJOONI", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE820Y01021", "curr_date": "Feb 06", "curr_time": "", "bse_nse_vol": 1806720, "exc_status": "Active", "traded_date": "Feb 06, 2026", "traded_date_str": "2026 02 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ajooni-biotech-1002898-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Ajooni Biotech Ltd Surges to Upper Circuit on Robust Buying Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/ajooni-biotech-ltd-surges-to-upper-circuit-on-robust-buying-pressure-3813953", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AjooniBiotechLt_stocks_hitting_upper_circuit_3813953.png", "date": "2026-02-01 10:00:15", "description": "Ajooni Biotech Ltd surged to its upper circuit limit on 1 Feb 2026, registering a maximum daily gain of 9.25% amid robust buying interest and heightened investor participation. The stock’s sharp rally outpaced its sector and benchmark indices, reflecting renewed optimism despite its current sell rating and micro-cap status." }, { "title": "Ajooni Biotech Gains 1.04%: 2 Key Factors Driving the Week’s Mixed Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/ajooni-biotech-gains-104-2-key-factors-driving-the-weeks-mixed-momentum-3812784", "imagepath": "", "date": "2026-01-31 13:01:13", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 27:</strong> Stock dips 0.52% amid broader market gains</p>\n <p><strong>Jan 28:</strong> Price rebounds 2.09% on increased volume</p>\n <p><strong>Jan 29:</strong> Profit-taking leads to 1.79% decline</p>\n <p><strong>Jan 30:</strong> Strong quarterly results lift stock 1.30%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.3.85</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.3.89</div><div class=\"stat-change positive\">+1.04..." }, { "title": "Are Ajooni Biotech Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-ajooni-biotech-ltd-latest-results-good-or-bad-3811934", "imagepath": "", "date": "2026-01-30 19:27:33", "description": "Ajooni Biotech Ltd's latest financial results for Q3 FY26 present a complex picture of performance. The company reported a significant year-on-year revenue growth of 72.64%, reaching net sales of ₹58.75 crores, which is the highest quarterly sales figure in its recent history. This growth indicates successful order execution or potential market share gains in its pharmaceutical operations. Additionally, net profit rose to ₹1.65 crores, reflecting a substantial year-on-year increase of 126.03%.\n\nHowever, despite the robust top-line growth, the company's profitability margins reveal ongoing challenges. The operating margin improved slightly to 5.16%, but the PAT margin contracted to 2.81%, down by 12 basis points sequentially. This suggests that while revenue is growing, the company is struggling to translate this growth into sustainable profitability, highlighting operational inefficiencies.\n\nThe financial m..." }, { "title": "Ajooni Biotech Ltd Reports Very Positive Quarterly Financial Performance Amidst Challenging Market Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/ajooni-biotech-ltd-reports-very-positive-quarterly-financial-performance-amidst-challenging-market-returns-3811746", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjooniBiotechLt_fintrenddot_3811746.png", "date": "2026-01-30 16:00:13", "description": "Ajooni Biotech Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, registering its highest quarterly revenue and profitability metrics in recent history. Despite this operational upswing, the company’s stock continues to face headwinds in the broader market, reflecting a complex interplay between fundamental progress and investor sentiment." }, { "title": "Ajooni Biotech Q3 FY26: Revenue Surge Masks Underlying Profitability Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/ajooni-biotech-q3-fy26-revenue-surge-masks-underlying-profitability-concerns-3811668", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjooniBiotech_quaterlyResult_3811668.png", "date": "2026-01-30 14:35:03", "description": "Ajooni Biotech Ltd., a micro-cap pharmaceutical company, reported a striking 85.10% quarter-on-quarter revenue surge in Q3 FY26, with net sales reaching ₹58.75 crores compared to ₹31.74 crores in the previous quarter. Net profit for the quarter stood at ₹1.65 crores, marking a 77.42% sequential increase from ₹0.93 crores in Q2 FY26. However, the stock has remained under severe pressure, declining 46.65% over the past year and trading at ₹3.90 against a market capitalisation of ₹67.18 crores, reflecting persistent investor concerns about the company's profitability trajectory and operational efficiency." }, { "title": "Ajooni Biotech Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajooni-biotech-ltd-is-rated-sell-3810959", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjooniBiotechLt_mojoScore_3810959.png", "date": "2026-01-30 10:11:27", "description": "Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating was revised at the start of the year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 30 January 2026, providing investors with an up-to-date view of the company’s position." }, { "title": "Ajooni Biotech Ltd is Rated Sell by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajooni-biotech-ltd-is-rated-sell-by-marketsmojo-3793905", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjooniBiotechLt_mojoScore_3793905.png", "date": "2026-01-19 10:10:46", "description": "Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating was revised at the start of the year, the analysis and financial metrics presented here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Ajooni Biotech Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajooni-biotech-ltd-is-rated-sell-3784270", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjooniBiotechLt_mojoScore_3784270.png", "date": "2026-01-07 10:10:55", "description": "Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Ajooni Biotech Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajooni-biotech-ltd-is-rated-strong-sell-3769524", "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AjooniBiotechLt_mojoScore_3769524.png", "date": "2025-12-25 15:13:16", "description": "Ajooni Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook." } ], "total": 104, "sid": "1002898", "stock_news_url": "https://www.marketsmojo.com/news/ajooni-biotech-1002898" }, "announcements": [ { "details": "Ajooni Biotech Limited has informed the Exchange regarding Board meeting held on November 13, 2019.", "source": "NSE", "caption": "Ajooni Biotech Limited - Outcome of Board Meeting", "datetime": "14-Nov-2019" }, { "details": "Ajooni Biotech Limited with respect to announcement dated 14-Oct-2019, that the Board of Directors in their meeting held on October 14, 2019 has considered and approved the resignation of Ms. Kanika Sapra, Company Secretary and Compliance Officer of the Company. On basis of above the Company is required to clarify following: 1. Date of resignation of Ms. Kanika Sapra. The response of the Company is awaited.", "source": "NSE", "caption": "Ajooni Biotech Limited - Clarification", "datetime": "23-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Ajooni Biotech Ltd has announced <strong>2:10</strong> stock split, ex-date: 07 Oct 22", "dt": "2022-10-07", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Ajooni Biotech Ltd has announced <strong>1:9</strong> bonus issue, ex-date: 10 Mar 21", "dt": "2021-03-10", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Ajooni Biotech Ltd has announced <strong>1:1</strong> rights issue, ex-date: 07 May 24", "dt": "2024-05-07", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

Jan 27: Stock dips 0.52% amid broader market gains

Jan 28: Price rebounds 2.09% on increased volume

Jan 29: Profit-taking leads to 1.79% decline

Jan 30: Strong quarterly results lift stock 1.30%

Read full news article

Are Ajooni Biotech Ltd latest results good or bad?

2026-01-30 19:27:33

Ajooni Biotech Ltd's latest financial results for Q3 FY26 present a complex picture of performance. The company reported a significant year-on-year revenue growth of 72.64%, reaching net sales of ₹58.75 crores, which is the highest quarterly sales figure in its recent history. This growth indicates successful order execution or potential market share gains in its pharmaceutical operations. Additionally, net profit rose to ₹1.65 crores, reflecting a substantial year-on-year increase of 126.03%. However, despite the robust top-line growth, the company's profitability margins reveal ongoing challenges. The operating margin improved slightly to 5.16%, but the PAT margin contracted to 2.81%, down by 12 basis points sequentially. This suggests that while revenue is growing, the company is struggling to translate this growth into sustainable profitability, highlighting operational inefficiencies. The financial m...

Read full news article

Ajooni Biotech Ltd Reports Very Positive Quarterly Financial Performance Amidst Challenging Market Returns

2026-01-30 16:00:13

Ajooni Biotech Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, registering its highest quarterly revenue and profitability metrics in recent history. Despite this operational upswing, the company’s stock continues to face headwinds in the broader market, reflecting a complex interplay between fundamental progress and investor sentiment.

Read full news article

Ajooni Biotech Q3 FY26: Revenue Surge Masks Underlying Profitability Concerns

2026-01-30 14:35:03

Ajooni Biotech Ltd., a micro-cap pharmaceutical company, reported a striking 85.10% quarter-on-quarter revenue surge in Q3 FY26, with net sales reaching ₹58.75 crores compared to ₹31.74 crores in the previous quarter. Net profit for the quarter stood at ₹1.65 crores, marking a 77.42% sequential increase from ₹0.93 crores in Q2 FY26. However, the stock has remained under severe pressure, declining 46.65% over the past year and trading at ₹3.90 against a market capitalisation of ₹67.18 crores, reflecting persistent investor concerns about the company's profitability trajectory and operational efficiency.

Read full news article

Ajooni Biotech Ltd is Rated Sell

2026-01-30 10:11:27

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating was revised at the start of the year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 30 January 2026, providing investors with an up-to-date view of the company’s position.

Read full news article

Ajooni Biotech Ltd is Rated Sell by MarketsMOJO

2026-01-19 10:10:46

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating was revised at the start of the year, the analysis and financial metrics presented here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Ajooni Biotech Ltd is Rated Sell

2026-01-07 10:10:55

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Ajooni Biotech Ltd is Rated Strong Sell

2025-12-25 15:13:16

Ajooni Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Read full news article